Represents Grant table in the DB

GET /v1/grants?page%5Bnumber%5D=1405&sort=approved
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/vnd.api+json
Vary: Accept

{
    "links": {
        "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=approved",
        "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=approved",
        "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=approved",
        "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=approved"
    },
    "data": [
        {
            "type": "Grant",
            "id": "12295",
            "attributes": {
                "award_id": "1R03CA280302-01",
                "title": "Tumor downstaging with small molecule therapeutics to enhance Uveal Melanoma metastasis eradication by B7-H3 CAR T cells",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Cancer Institute (NCI)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 21448,
                        "first_name": "CONNIE L",
                        "last_name": "Sommers",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-20",
                "end_date": "2025-08-31",
                "award_amount": 167000,
                "principal_investigator": {
                    "id": 28194,
                    "first_name": "Cristina R.",
                    "last_name": "Ferrone",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 766,
                    "ror": "https://ror.org/02pammg90",
                    "name": "Cedars-Sinai Medical Center",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Uveal Melanoma (UM) is a rare cancer with an incidence of 5 cases per million in the United States. Nearly half UM patients develop isolated liver metastases due to the high tendency of UM cells to spread to the liver. No cure has been found for patients with metastatic UM (mUM). Tebentafusp, is the only FDA-approved therapy for mUM. However, it has shown modest improvements in terms of overall response and progression-free survival and its applicability is limited to only 40% of mUM patients. The lack of effective treatment options for mUM has prompted us to design a novel combinatorial immunotherapeutic strategy based on the use of Chimeric Antigen Receptor (CAR) T cells specifically redirected against B7-H3. The latter has been selected as the target of our immunotherapeutic strategy, since it is highly expressed on UM cell lines and mUM tumor tissue samples, but has a limited expression on normal tissues. It is a general experience that CAR T cell-based immunotherapy is not effective in eradicating solid tumors both in preclinical and clinical investigations. This result is likely caused by multiple mechanisms, among which the major role is played by their use in hosts with high tumor load; the resulting unfavorable effector to target (E:T) ratio in the tumor microenvironment has a negative impact on the antitumor activity of CAR T cells, as indicated by the results generated by preclinical and clinical investigations. The information in the literature and our preliminary results have provided the rationale to design a strategy which applies first a tumor debulking approach to reduce tumor load and then CAR T cell- based immunotherapy to eradicate UM metastases. We will use the combination of trametinib, a mitogen-activated protein kinase kinase inhibitor (MEKi) and of panobinostat, a histone deacetylase inhibitor (HDACi), since this combination has been shown to induce marked regression of UM liver metastases in mice. Furthermore, this combination does not affect B7- H3 expression by UM cells and the antitumor activity of B7-H3 CAR T cells. Therefore, after having shown that B7-H3 CAR T cells can recognize and eliminate UM cells surviving the treatment with the MEKi and HDACi combination, we will investigate whether tumor debulking induced by the MEKi and HDACi combination can enhance the ability of B7-H3 CAR T cells to eradicate UM liver metastases in NSG mice. Since one major limitation of CAR T cell-based therapy is represented by its potential toxicity and/or cytokine release syndrome, we have incorporated in our CAR construct an inducible caspase 9 safety switch which allows rapid elimination of CAR T cells in case of unexpected toxicities. If the results generated by our experiments are positive, they will have a major impact on the treatment of mUM.",
                "keywords": [
                    "Affinity",
                    "Awareness",
                    "CAR T cell therapy",
                    "CASP9 gene",
                    "CD276 gene",
                    "Cell Line",
                    "Cell Survival",
                    "Cells",
                    "Cellular immunotherapy",
                    "Clinical",
                    "Collaborations",
                    "Complex",
                    "Cytolysis",
                    "Data",
                    "Diagnosis",
                    "Disease",
                    "FDA approved",
                    "Generations",
                    "Goals",
                    "HDAC4 gene",
                    "HLA-A2 Antigen",
                    "Histone Deacetylase Inhibitor",
                    "Human",
                    "Immunotherapeutic agent",
                    "Immunotherapy",
                    "In Vitro",
                    "Incidence",
                    "Investigation",
                    "Label",
                    "Literature",
                    "Liver",
                    "MEKs",
                    "Mediating",
                    "Melanoma Cell",
                    "Metastatic Neoplasm to the Liver",
                    "Methodology",
                    "Mitogen-Activated Protein Kinase Kinases",
                    "Monitor",
                    "Mus",
                    "Neoplasm Metastasis",
                    "Normal Cell",
                    "Normal tissue morphology",
                    "Operative Surgical Procedures",
                    "Patients",
                    "Play",
                    "Predisposition",
                    "Progression-Free Survivals",
                    "Proteins",
                    "Residual state",
                    "Role",
                    "SILV gene",
                    "Safety",
                    "Solid Neoplasm",
                    "Specificity",
                    "T cell therapy",
                    "T-Cell Receptor",
                    "T-Lymphocyte",
                    "Testing",
                    "Time",
                    "Tissue Sample",
                    "Toxic effect",
                    "Translating",
                    "Tumor Antigens",
                    "Tumor Burden",
                    "Tumor Debulking",
                    "Tumor Tissue",
                    "Tumor Volume",
                    "United States",
                    "Uveal Melanoma",
                    "bioluminescence imaging",
                    "cancer cell",
                    "chimeric antigen receptor",
                    "chimeric antigen receptor T cells",
                    "clinical investigation",
                    "combinatorial",
                    "cytokine release syndrome",
                    "cytotoxic",
                    "design",
                    "effective therapy",
                    "expectation",
                    "experience",
                    "experimental study",
                    "gp100 Antigen",
                    "improved",
                    "in vivo",
                    "inhibitor",
                    "kinase inhibitor",
                    "mortality",
                    "mouse model",
                    "novel",
                    "pre-clinical",
                    "rare cancer",
                    "response",
                    "small molecule therapeutics",
                    "tumor",
                    "tumor growth",
                    "tumor microenvironment"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12296",
            "attributes": {
                "award_id": "1C06OD036029-01",
                "title": "UNC BSL3 Core Facility",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "NIH Office of the Director"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 28173,
                        "first_name": "YONG",
                        "last_name": "Chen",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-06",
                "end_date": "2028-05-31",
                "award_amount": 7916788,
                "principal_investigator": {
                    "id": 28195,
                    "first_name": "Craig A",
                    "last_name": "Fletcher",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 817,
                    "ror": "",
                    "name": "UNIV OF NORTH CAROLINA CHAPEL HILL",
                    "address": "",
                    "city": "",
                    "state": "NC",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "/ ABSTRACT: The central goal of this project is to construct a 10,000 square feet biosafety level 3 (BSL3) research laboratory core facility to promote readiness to respond to future pandemics. Infectious diseases pose a severe and increasing threat to human health, especially in communities that lack access to health care. UNC programs will soon exceed current infrastructure capacity due to increase demand. A strategic review of our microbial pathogenesis and infectious disease community concluded that urgent action was essential to support the high containment programs. Among the barriers to the growth of research was a lack of access to critical technologies and animal space within the existing BSL3 laboratories. This transformative BSL3 core facility will allow UNC to expand to meet current and projected research needs in the UNC School of Medicine, School of Pharmacy, and Gillings School of Global Public Health. UNC has engaged multiple stakeholders across the research community to design and construct a centralized BSL3 suite to characterize the immune responses to coronavirus and other emerging viral pathogens and learn about what drives immune response, disease progression, and protection against future infection. The proposal will attain four objectives: 1. Design and construct a high containment facility to bring investigators working on emerging and re-emerging infections together; 2. Enable access to specialized instrumentation including aerobiology and imaging equipment for supporting high containment research; 3. Create institution-wide core space to allow recruitment of new investigators to the infectious disease research community by increasing usable laboratory space in the BSL3 facility and purchasing new equipment that will serve investigators within the many UNC centers, institutes, and departments and their nationwide collaborators; 4. Enhance UNC's ability to lead the rapid response generating new therapeutics and vaccines to save lives on a local, national, and even global level.",
                "keywords": [
                    "Animals",
                    "Communicable Diseases",
                    "Communities",
                    "Containment",
                    "Core Facility",
                    "Coronavirus",
                    "Disease Progression",
                    "Equipment",
                    "Future",
                    "Gills",
                    "Goals",
                    "Growth",
                    "Health",
                    "Human",
                    "Image",
                    "Immune response",
                    "Infection",
                    "Infectious Diseases Research",
                    "Infrastructure",
                    "Institution",
                    "Laboratories",
                    "Laboratory Research",
                    "Learning",
                    "Pathogenesis",
                    "Pharmacy Schools",
                    "Public Health",
                    "Readiness",
                    "Research",
                    "Research Personnel",
                    "Research Project Grants",
                    "Schools",
                    "Technology",
                    "biosafety level 3 facility",
                    "design and construction",
                    "future pandemic",
                    "health care availability",
                    "instrumentation",
                    "medical schools",
                    "microbial",
                    "novel therapeutics",
                    "novel vaccines",
                    "pathogenic virus",
                    "programs",
                    "recruit",
                    "response",
                    "square foot",
                    "usability"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12297",
            "attributes": {
                "award_id": "3UM1DA049417-04S1",
                "title": "Optimizing HEALing in Ohio Communities (OHiO)-Health Equity Supplement",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute on Drug Abuse (NIDA)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 20583,
                        "first_name": "KEISHER S",
                        "last_name": "Highsmith",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-15",
                "end_date": "2024-03-31",
                "award_amount": 799825,
                "principal_investigator": {
                    "id": 9970,
                    "first_name": "Bridget J",
                    "last_name": "Freisthler",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 778,
                            "ror": "",
                            "name": "OHIO STATE UNIVERSITY",
                            "address": "",
                            "city": "",
                            "state": "OH",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [
                    {
                        "id": 28196,
                        "first_name": "T John",
                        "last_name": "WINHUSEN",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "awardee_organization": {
                    "id": 778,
                    "ror": "",
                    "name": "OHIO STATE UNIVERSITY",
                    "address": "",
                    "city": "",
                    "state": "OH",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "This supplement aims to explore the impact of the infusion of health equity principles on overdose prevention strategies during implementation of the Communities That Heal (CTH) intervention as part of the HEALing Communities Study (HCS). The HCS is a multi-site, parallel arm, cluster randomized, wait-list controlled trial evaluating the impact of the CTH intervention compared with usual care in wait-list communities, on overdose deaths. The overall goal of the HCS is to reduce opioid overdose deaths by 40% in 67 HCS communities across four states. Communities form coalitions to make shared decisions about what overdose prevention strategies to implement and how best to implement them, particularly strategies that promote Overdose Prevention Education and Naloxone Distribution (OEND) and Medications for Opioid Use Disorder (MOUD). While it is known that minoritized communities (whether due to race, ethnicity, gender, or LGBTQIA+ status) have less and poorer access to treatment for Opioid Use Disorder (OUD) and associated disparities in outcomes, at its outset, HCS did not explicitly aim to reduce disparities or measure the effect of centering equity on overdose prevention. This approach changed in 2020 with acute awareness of the racial and ethnic disparities within the COVID epidemic and the racial awakening in response to the George Floyd killing. This supplement will leverage the existing infrastructure and study staff of its parent study to analyze survey and other qualitative data already collected. The primary data sources will include surveys of coalition members, completed at four time points during the study period; the Opioid-Overdose Reduction Continuum of Care Approach Tracker (ORCCAT), completed monthly by study staff, that includes overdose prevention information by strategy, sector, venue, population served, coalition approval date, implementation plan developed, date started, number of partners/practices associated with strategy, and mode of delivery; and REACH data, completed by study staff monthly once each strategy is implemented that includes information on number of persons reached and demographics of those reached (e.g., race, ethnicity, sex, age). Data analysis will include both quantitative analysis examining associations between survey answers regarding health equity topics and incorporation of equity into strategies, as well as qualitative analysis examining how coalitions discussed and prioritized equity topics. This study will be guided by the parent study’s PRISM/RE-AIM(S) conceptual framework with a novel health equity lens to examine how diversifying coalitions and infusing opioid overdose prevention strategies with health equity principles may help reach minoritized communities and how these contextual factors and processes may interact to promote or impede health equity. Results from this study may be used to inform policies, strategies, and practices for incorporating health equity principles when implementing overdose prevention strategies.",
                "keywords": [
                    "Achievement",
                    "Acute",
                    "Address",
                    "Adoption",
                    "Age",
                    "Attention",
                    "Awareness",
                    "Black Populations",
                    "COVID-19 pandemic",
                    "Collaborations",
                    "Communities",
                    "Community Health",
                    "Continuity of Patient Care",
                    "Data",
                    "Data Analyses",
                    "Data Sources",
                    "Death Rate",
                    "Decision Making",
                    "Disparity",
                    "Equity",
                    "Ethnic Origin",
                    "Frequencies",
                    "Gender",
                    "Geography",
                    "Goals",
                    "Grant",
                    "Health",
                    "Health Services Accessibility",
                    "Homelessness",
                    "Individual",
                    "Infrastructure",
                    "Infusion procedures",
                    "Intervention",
                    "Kentucky",
                    "Learning",
                    "Legal system",
                    "Manuscripts",
                    "Maps",
                    "Massachusetts",
                    "Measures",
                    "Methods",
                    "Modeling",
                    "Naloxone",
                    "National Institute of Drug Abuse",
                    "Nature",
                    "New York",
                    "Not Hispanic or Latino",
                    "Ohio",
                    "Outcome",
                    "Outcome Study",
                    "Overdose reduction",
                    "Parents",
                    "Participant",
                    "Persons",
                    "Pharmaceutical Preparations",
                    "Phase",
                    "Policies",
                    "Population",
                    "Prevention education",
                    "Prevention strategy",
                    "Process",
                    "Protocols documentation",
                    "Publications",
                    "Publishing",
                    "Race",
                    "Racial Equity",
                    "Randomized",
                    "Reach  Effectiveness  Adoption  Implementation  and Maintenance",
                    "Readiness",
                    "Reporting",
                    "Research Personnel",
                    "Resources",
                    "Respondent",
                    "Rural",
                    "Site",
                    "Special Population",
                    "Surveys",
                    "Time",
                    "Training",
                    "Underserved Population",
                    "United States Substance Abuse and Mental Health Services Administration",
                    "Waiting Lists",
                    "Work",
                    "arm",
                    "black men",
                    "comparison intervention",
                    "contextual factors",
                    "demographics",
                    "design",
                    "disparity reduction",
                    "ethnic disparity",
                    "ethnic diversity",
                    "ethnic minority",
                    "ethnic minority population",
                    "healing",
                    "health equity",
                    "implementation strategy",
                    "insight",
                    "medication for opioid use disorder",
                    "meetings",
                    "member",
                    "minority communities",
                    "novel",
                    "opioid mortality",
                    "opioid overdose",
                    "opioid use disorder",
                    "overdose death",
                    "overdose prevention",
                    "racial disparity",
                    "racial minority",
                    "racial minority population",
                    "response",
                    "satisfaction",
                    "sex",
                    "shared decision making",
                    "social health determinants",
                    "social stigma",
                    "sociodemographics",
                    "tool",
                    "treatment as usual",
                    "trend"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12298",
            "attributes": {
                "award_id": "1U18HS029905-01",
                "title": "Improving Access to Multidisciplinary Care for patients with long COVID",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "Agency for Healthcare Research and Quality (AHRQ)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 28197,
                        "first_name": "Leeann",
                        "last_name": "Comfort",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-30",
                "end_date": "2028-09-29",
                "award_amount": 999951,
                "principal_investigator": {
                    "id": 28198,
                    "first_name": "Jessica Anne",
                    "last_name": "Bender",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [
                    {
                        "id": 28199,
                        "first_name": "Janna L",
                        "last_name": "Friedly",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    },
                    {
                        "id": 28200,
                        "first_name": "Nikki",
                        "last_name": "Gentile",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "awardee_organization": {
                    "id": 159,
                    "ror": "https://ror.org/00cvxb145",
                    "name": "University of Washington",
                    "address": "",
                    "city": "",
                    "state": "WA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The proposed project seeks to expand the existing UW multidisciplinary long COVID clinic (the Post COVID Rehabilitation and Recovery clinic) to improve access and coordination of care for patients with long COVID. This project will allow the team to improve care delivery for all patients, but will emphasize improving access to multidisciplinary care for underserved patients including patients in rural communities, Alaska, and in Latinx, Native American, and SE Asian communities. With additional funding, we will make an enormous impact on a large region throughout WWAMI, focusing initially on Washington and Alaska, and Idaho, Montana, Wyoming in the later years. The aims of this proposed project include Aim 1: Improve clinical care delivery and expand access to the UW PCRRC. The goal of this aim is to improve access and care delivery for patients from Washington and Alaska that are referred to the Post-COVID Rehabilitation and Recovery clinic. The key areas that we will be expanding in this project include: 1) coordination of care; 2) behavioral health support; 3) vocational services; and 4) electronic consults. Aim 2: Engage underserved communities to enhance long COVID education and connection to local resources. The overall goal of our community engagement activities will be to foster authentic longitudinal relationships, promote ongoing collaborations and address the needs of community members. We will accomplish this by: 1) forming a community advisory board to guide our engagement activities; 2) producing publicly accessible educational webinars (community conversations) addressing COVID and long COVID; 3) producing culturally responsive patient education materials on long COVID in English, Spanish, and SE Asian languages; and 4) participating in community events including town hall meetings, community health fairs, pop-up vaccination events to share information about the UW long COVID clinic and long COVID. Aim 3: Improve patient access in the WWAMI region by training a network of clinicians specializing in long COVID care. In this aim, we will provide ongoing education and support to community PCPs, psychologists, and physical therapists with a focus on providers in under-resourced areas across the WWAMI region, including rural areas. We will accomplish this by: 1) In partnership with the Washington State DOH, we will create an advanced training certificate program for long COVID. 2) We will conduct monthly interactive case-based webinars. 3) We will also identify local physician and physical therapy leads who can be trained to be local experts in the care of patients with long COVID and are a part of our extended UW PCRRC network. 4) We will hold weekly virtual office hours that are pre-specified with a scheduling system to allow community providers to discuss cases and ask questions that will help them with their own management of patients with long COVID.",
                "keywords": [],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12299",
            "attributes": {
                "award_id": "1R21GM150088-01",
                "title": "Toward synthetic chemically defined mRNA for human therapeutics",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of General Medical Sciences (NIGMS)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 22262,
                        "first_name": "KADIR",
                        "last_name": "Aslan",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-15",
                "end_date": "2025-08-31",
                "award_amount": 205541,
                "principal_investigator": {
                    "id": 28201,
                    "first_name": "Keith Thomas",
                    "last_name": "Gagnon",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1149,
                    "ror": "",
                    "name": "WAKE FOREST UNIVERSITY HEALTH SCIENCES",
                    "address": "",
                    "city": "",
                    "state": "NC",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Messenger RNA, or mRNA, and its translation into protein lies at the heart of the central dogma of molecular biology. Converting this basic cellular mechanism into a therapeutic opportunity was the basis of the first two successful COVID-19 vaccines. This technology has the potential to be further advanced into much broader therapeutic modalities, such as a gene replacement medicine for genetic diseases. Currently, mRNA molecules for human therapeutics are generated from biological enzymatic reactions. While this process can create large amounts of material, it suffers from several drawbacks. These include multiple steps in manufacturing, purity, and patient safety. However, the greatest shortcoming is the rapid turnover of mRNA in the body, which severely limits its duration of effect and tunability for a genetic medicine. Unless addressed, this shortcoming will handicap mRNA therapeutics from ever becoming more than a vaccine technology.  Chemical modification was the missing ingredient and final piece necessary for the realization of other recently FDA-approved nucleic acid drugs, including antisense oligonucleotides and small interfering RNAs. Chemical modifications enabled nuclease protection, significantly extended drug half-lives, and predictable pharmacological tuning. Likewise, realizing the full potential of mRNA as a human therapeutic will ultimately come down to chemistry.  RNA can be chemically synthesized in small fragments. However, no technology exists to easily create long chemically defined translation-competent mRNA molecules. In addition, most of the chemical modifications extensively characterized for their beneficial properties for other nucleic acid therapeutics have not been explored in mRNA research, and certainly not in a therapeutic context. This project proposes to tackle these challenges by generating full-length mRNAs from chemically synthesized fragments, investigating the impact of diverse chemical modifications on mRNA translation, and applying new synthetic chemical methods to make longer mRNAs suitable for human therapeutics.  The aims of this proposal are to 1) evaluate the impact of specific nucleotide modifications on model mRNA translation in cells and in vitro, 2) assess the compatibility of triazole linkages with mRNA translation and on-resin “click” chemistry for solid-phase chemical synthesis of longer mRNA, and 3) demonstrate long mRNA chemical synthesis and its potential for therapeutic development in cells and in vivo. The results of this focused project should pioneer a paradigm-shifting approach to mRNA therapeutic development and open new possibilities for conferring better control over the drug properties of mRNA.",
                "keywords": [
                    "Achievement",
                    "Address",
                    "Antisense Oligonucleotides",
                    "Azoles",
                    "Bacteria",
                    "Biochemical Reaction",
                    "Biological",
                    "Bypass",
                    "COVID-19 vaccine",
                    "Cells",
                    "Chemicals",
                    "Chemistry",
                    "DNA",
                    "Development",
                    "Disease",
                    "Double-Stranded RNA",
                    "Enzymes",
                    "FDA approved",
                    "Formulation",
                    "Gene Expression",
                    "Generations",
                    "Genetic",
                    "Genetic Diseases",
                    "Genetic Medicine",
                    "Half-Life",
                    "Heart",
                    "Human",
                    "In Vitro",
                    "Length",
                    "Libraries",
                    "Medicine",
                    "Messenger RNA",
                    "Methodology",
                    "Methods",
                    "Minor",
                    "Modality",
                    "Modeling",
                    "Modification",
                    "Molecular Biology",
                    "Mus",
                    "Nucleic Acids",
                    "Nucleotides",
                    "Open Reading Frames",
                    "Patients",
                    "Pharmaceutical Preparations",
                    "Phase",
                    "Plant Resins",
                    "Process",
                    "Production",
                    "Property",
                    "Proteins",
                    "RNA",
                    "RNA chemical synthesis",
                    "Reporter",
                    "Research",
                    "Ribose",
                    "Ribosomes",
                    "S phase",
                    "Safety",
                    "Science",
                    "Site",
                    "Small Interfering RNA",
                    "Solid",
                    "Technology",
                    "Testing",
                    "Therapeutic",
                    "Time",
                    "Tissues",
                    "Toxin",
                    "Translations",
                    "Vaccines",
                    "Vertebral column",
                    "chemical synthesis",
                    "design",
                    "drug development",
                    "gene replacement",
                    "gene therapy",
                    "immunogenic",
                    "in vivo",
                    "innovation",
                    "lipid nanoparticle",
                    "manufacture",
                    "nuclease",
                    "nucleic acid-based therapeutics",
                    "patient safety",
                    "pharmacologic",
                    "sugar",
                    "therapeutic RNA",
                    "therapeutic development",
                    "therapeutic protein"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12300",
            "attributes": {
                "award_id": "1R01AG079554-01A1",
                "title": "Genotyping the Understanding America Study to generate novel opportunities for research on cognitive functioning and dementia",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute on Aging (NIA)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 9723,
                        "first_name": "AMELIA WILKES",
                        "last_name": "Karraker",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-15",
                "end_date": "2028-05-31",
                "award_amount": 2763177,
                "principal_investigator": {
                    "id": 28202,
                    "first_name": "Jessica",
                    "last_name": "Faul",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [
                    {
                        "id": 28203,
                        "first_name": "Titus Johannes",
                        "last_name": "Galama",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "awardee_organization": {
                    "id": 152,
                    "ror": "https://ror.org/03taz7m60",
                    "name": "University of Southern California",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "/ abstract Cognitive impairment and dementia are prevalent and cause significant morbidity and substantial financial and social burden. With the rising number of cases of dementia in the U.S. and worldwide, there is an urgent need to identify opportunities for preventing or delaying its onset.  In this infrastructure proposal, we propose to make use of recent advances in genetics by genotyping the Understanding America Study (UAS) and constructing “polygenic scores” (PGSs), indexes that aggregate the small effects of millions of genetic variants from across the genome, for use in social-science studies of factors that increase or mitigate the risk of Alzheimer’s Disease and Related Dementias (ADRD). The UAS, a probability- based Internet panel housed at the Center for Economic and Social Research (CESR) at the University of Southern California, longitudinally tracks a sample of approximately 10,000 adults in the U.S. (growing to at least 20,000 by 2026). It combines several sources of information, including from surveys, wearable devices, administrative linkages, and contextual data, and has several unique features: it provides the opportunity for on- demand data collection on short notice; it allows for the collection of data at higher frequencies and for the possibility of initiating new data collection in response to major societal events (such as the COVID-19 pandemic), or triggered by events in the lives of respondents (such as “burst surveys” fielded when there is an important change in the life of a panel member); it can be used to take advantage of natural experiments; it allows for frequent collection (once or twice a month) of paradata (computer user-behavior from surveys, e.g., errors and processing speed gleaned from keystrokes) which is predictive of cognitive functioning.  Ours is not a genome-wide association study (GWAS). Instead, we will use genetic variants (SNPs) identified from existing large, replicated GWASs, to create polygenic scores (PGSs), and exploit unique UAS capabilities, afforded by its Internet mode of operation, to better understand ADRD risk in a nationally representative sample. We will use PGSs, as well as APOE-ε4 status, together with longitudinal health, cognitive, behavioral, and environmental measures, to: (i) identify populations at risk of cognitive decline, (ii) collect new data for causal inferences of the effects of ADRD risk/protective factors on cognition by genetic ADRD risk, and iii) study the role of genetics in the resilience to adverse life events affecting cognitive functioning.  By making publicly available a large number of genetic measures for ADRD, cognitive decline, and associated protective/risk factors (e.g., physical activity, cardiovascular risk [diabetes, obesity, smoking and hypertension], diet, sleep, pollution, and education, among others), and through our own research, we seek to stimulate the use of unique UAS capabilities in economic and social-science research of ADRD, cognitive impairment, and cognitive decline.",
                "keywords": [
                    "Address",
                    "Adult",
                    "Affect",
                    "Alzheimer&apos",
                    "s Disease",
                    "Alzheimer&apos",
                    "s disease related dementia",
                    "Area",
                    "Behavior",
                    "Behavioral",
                    "COVID-19 pandemic",
                    "California",
                    "Caregivers",
                    "Cessation of life",
                    "Cognition",
                    "Cognitive",
                    "Collection",
                    "Communities",
                    "Complex",
                    "Computers",
                    "Creativeness",
                    "DNA",
                    "Data",
                    "Data Collection",
                    "Dementia",
                    "Diabetes Mellitus",
                    "Diet",
                    "Economics",
                    "Education",
                    "Educational workshop",
                    "Employment",
                    "Environment",
                    "Event",
                    "Family",
                    "Frequencies",
                    "Genetic",
                    "Genetic Predisposition to Disease",
                    "Genetic Risk",
                    "Genetic study",
                    "Genome",
                    "Genotype",
                    "Glean",
                    "Health",
                    "Hypertension",
                    "Impaired cognition",
                    "Individual",
                    "Infrastructure",
                    "Internet",
                    "Life",
                    "Measures",
                    "Monitor",
                    "Morbidity - disease rate",
                    "National Institute on Aging",
                    "Natural experiment",
                    "Neurobehavioral Manifestations",
                    "Obesity",
                    "Occupations",
                    "Outcome",
                    "Participant",
                    "Phenotype",
                    "Physical activity",
                    "Physical environment",
                    "Policies",
                    "Policy Maker",
                    "Pollution",
                    "Populations at Risk",
                    "Probability",
                    "Publishing",
                    "Quasi-experiment",
                    "Recording of previous events",
                    "Research",
                    "Research Personnel",
                    "Respondent",
                    "Risk",
                    "Risk Factors",
                    "Role",
                    "Salivary",
                    "Sampling",
                    "Sleep",
                    "Smoking",
                    "Social Environment",
                    "Social Sciences",
                    "Societies",
                    "Source",
                    "Standardization",
                    "Surveys",
                    "Tablets",
                    "Unemployment",
                    "Universities",
                    "Variant",
                    "Weight",
                    "apolipoprotein E-4",
                    "behavioral response",
                    "cardiovascular risk factor",
                    "cognitive function",
                    "data storage site",
                    "dementia risk",
                    "field survey",
                    "genetic variant",
                    "genome wide association study",
                    "indexing",
                    "innovation",
                    "member",
                    "novel",
                    "operation",
                    "phenotypic data",
                    "prevent",
                    "processing speed",
                    "protective factors",
                    "recruit",
                    "resilience",
                    "response",
                    "risk mitigation",
                    "social",
                    "social science research",
                    "trait",
                    "wearable device"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12301",
            "attributes": {
                "award_id": "1R21AI178391-01",
                "title": "Impacts of Adaptive Coronavirus Evolution on Viral Membrane Fusion",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 27781,
                        "first_name": "Mary Katherine Bradford",
                        "last_name": "Plimack",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-14",
                "end_date": "2025-08-31",
                "award_amount": 244800,
                "principal_investigator": {
                    "id": 28021,
                    "first_name": "Thomas Miller",
                    "last_name": "Gallagher",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1513,
                    "ror": "https://ror.org/04b6x2g63",
                    "name": "Loyola University Chicago",
                    "address": "",
                    "city": "",
                    "state": "IL",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The continuous adaptation of SARS-CoV-2 generates variants of concern (VOC). New VOCs arise independently and outcompete previous ones, consistent with ever increasing viral fitness. Most VOC adaptations reside in the spikes (S), the complex multidomain glycoprotein trimers that bind viruses to cells and mediate virus-cell membrane fusion. Well-characterized adaptations in the S receptor binding domains (RBDs) alter RBD structural dynamics, receptor affinities, and antibody interactions. However, adaptations in other S domains remain largely under-evaluated. This includes the S2 domains that execute virus-cell membrane fusion. This proposal aims to elucidate consequences of VOC adaptive changes in the S2 domains. The current VOC, omicron (o), has accumulated over six S2 mutations. Our central objective is to evaluate the ways these and other S2 adaptations alter S protein dynamics to facilitate human cell entry. We will utilize a collection of viral membrane fusion and cell entry assay systems to determine whether S2 changes reset the dynamics of transient S protein intermediate states. These transitory states include RBD elevations that control receptor binding and S2 refoldings from prefusion to fusion intermediate and through to postfusion configurations. Our assay systems will employ fusion-competent virus-like particles (VLPs) for sensitive evaluation of entry steps, soluble receptors as probes for RBD exposures, HR2 peptides for detection of specific S transitional intermediates, replication-competent VSVSARS-CoV-2-S for selecting HR2 peptide-resistant variants, and SARS-CoV-2 replicons and recombinant SARS-CoV-2 viruses for convincingly assigning specific S2 amino acid substitutions to consequential redirection of virus-cell entry pathways. Our preliminary results suggest that omicron S2 adaptations operate allosterically to alter S-receptor interactions. The first aim will determine how S2 fusion domains control RBDs and their interactions with receptors. We will identify specific VOC S2 mutations that control receptor reactivity and S stability. We will determine how these mutations change viral entry requirements. Our initial results also suggest that omicron S2 mutations change the pace of the conformational transitions facilitating membrane fusion. The second aim will determine how S2 mutations control dynamics of fusion domains. We will determine whether the rates of S2 structural transitions vary between VOCs. We will also select and characterize variants resistant to inhibitors of the S2 structural dynamics and will find out whether these resistant variants have unique requirements for the receptors and proteases that determine cell susceptibility to infection. The results of this study will clarify currently obscure selective forces driving the human adaptation of past (α, β, γ, δ), current (ο), and future VOCs. We expect the results will illuminate properties of the membrane fusion – inducing S2 domains in ways that reveal new targets for inhibition of CoV entry.",
                "keywords": [
                    "2019-nCoV",
                    "Affinity",
                    "Amino Acid Substitution",
                    "Amino Acids",
                    "Animals",
                    "Antibodies",
                    "Apical",
                    "Binding",
                    "Biochemical",
                    "Biological",
                    "Biological Assay",
                    "Cell membrane",
                    "Cells",
                    "Collection",
                    "Communication",
                    "Communities",
                    "Complex",
                    "Coronavirus",
                    "Coronavirus spike protein",
                    "Detection",
                    "Distant",
                    "Endocytosis",
                    "Engineering",
                    "Equilibrium",
                    "Evaluation",
                    "Evolution",
                    "Future",
                    "Glycoproteins",
                    "Goals",
                    "Human",
                    "Infection",
                    "Kinetics",
                    "Link",
                    "Measures",
                    "Mediating",
                    "Membrane Fusion",
                    "Middle East Respiratory Syndrome Coronavirus",
                    "Molecular Conformation",
                    "Mutation",
                    "Pathway interactions",
                    "Peptide Hydrolases",
                    "Peptides",
                    "Predisposition",
                    "Property",
                    "Protein Conformation",
                    "Protein Dynamics",
                    "Proteins",
                    "Receptor Cell",
                    "Recombinants",
                    "Replicon",
                    "Resistance",
                    "SARS-CoV-2 B.1.1.529",
                    "SARS-CoV-2 spike protein",
                    "SARS-CoV-2 variant",
                    "Site",
                    "Structure",
                    "Surface",
                    "System",
                    "Variant",
                    "Viral",
                    "Viral Drug Resistance",
                    "Virulence",
                    "Virus",
                    "Virus Receptors",
                    "Virus Shedding",
                    "Virus-like particle",
                    "conformational conversion",
                    "driving force",
                    "global health",
                    "inhibitor",
                    "insight",
                    "receptor",
                    "receptor binding",
                    "recombinant virus",
                    "resistance mutation",
                    "tool",
                    "transmission process",
                    "variants of concern",
                    "viral fitness",
                    "virus tropism"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12302",
            "attributes": {
                "award_id": "1DP2EB035891-01",
                "title": "A Novel Class of Synthetic Receptors to Empower the Age of mRNA Therapies",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "NIH Office of the Director"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 28204,
                        "first_name": "NICHOLE MARIE",
                        "last_name": "Daringer",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-19",
                "end_date": "2026-09-18",
                "award_amount": 1350770,
                "principal_investigator": {
                    "id": 28205,
                    "first_name": "Xiaojing J",
                    "last_name": "Gao",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 266,
                    "ror": "https://ror.org/00f54p054",
                    "name": "Stanford University",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The COVID vaccination campaigns have highlighted the promise of mRNA-mediated delivery as a novel therapeutic modality. One particular application is adoptive cell therapy, where immune cells are equipped with novel functions to treat diseases, e.g., expressing chimeric antigen receptors (CARs) in T cells to ablate cancer and other undesirable cells. Compared to DNA-based engineering of immune cells, mRNA has several advantages as a delivery vector, especially its superior safety profile, because it eliminates the risk of randomly inserting into the host genome and causing mutations, and its short half-life mitigates long-term adverse effects due to the persistence of the engineered cellular function. Instead of extracting cells from the patient, engineering them ex vivo, and then reinducing them, researchers have even directly delivered CAR-encoding mRNAs and created functional CAR T cells in vivo. This is appealing because it has the potential to make adoptive cell therapy accessible to the general public, its logistics almost as straightforward as manufacturing, distributing, and administering vaccine shots, in contrast to the costly ex vivo engineering process that will be limited to the privileged few.  Despite the great potential of mRNA-mediated adoptive cell therapy, there remains a critical need for tools that enhance targeting precision. It is very rare for a single surface marker, targeted by CAR, to unambiguously identify one target cell population. Therefore, “on-target/off-caner” killing is a major concern for CAR T cell therapies against cancer, and the same concern also applies to scenarios of ablating other cells, such as active fibroblasts in heart infarction or senescent cells. One elegant solution is synthetic receptors, most notably synthetic Notch, that detect a second marker and express CAR in response, effectively forming AND logic, where target cells are only killed when both inputs to the synthetic receptor and CAR are present. However, to our knowledge, all existing synthetic modular, programmable receptors operate at the DNA level, and are therefore incompatible with mRNA-mediated delivery.  Here we design and demonstrate the feasibility of a first-in-class synthetic modular receptor that operate at the RNA level. It converts ligand-induced dimerization events into the expression of arbitrary output proteins. Through extensive computational simulation and experimental optimization, we will expand the input/output repertoire of this receptor, establish its design principle, enable its encoding on single transcripts and delivery by mRNA, and take first steps towards improving the precision of ablating active fibroblasts to treat heart infarction.  The impact of such novel receptors is beyond adoptive cell therapy. For example, they can facilitate basic research by recording cells’ (e.g., neurons) exposure to specific signals (e.g., dopamine). They will benefit a variety of other biomedical applications too, from expressing antigens or cytokines in response to extracellular cues to enhance vaccine efficacy, to generating novel sense-and-respond capabilities for tissue engineering.",
                "keywords": [
                    "Ablation",
                    "Adoptive Cell Transfers",
                    "Adverse effects",
                    "Age",
                    "Antigens",
                    "Basic Science",
                    "CAR T cell therapy",
                    "Cell Extracts",
                    "Cell physiology",
                    "Cells",
                    "Computer Simulation",
                    "Cues",
                    "DNA",
                    "Dimerization",
                    "Disease",
                    "Dopamine",
                    "Engineering",
                    "Event",
                    "Exposure to",
                    "Fibroblasts",
                    "General Population",
                    "Genome",
                    "Half-Life",
                    "Immune",
                    "Ligands",
                    "Logic",
                    "Logistics",
                    "Malignant Neoplasms",
                    "Mediating",
                    "Messenger RNA",
                    "Modality",
                    "Mutation",
                    "Myocardial Infarction",
                    "Neurons",
                    "Output",
                    "Patients",
                    "Population",
                    "Precision therapeutics",
                    "Process",
                    "Proteins",
                    "Public Health",
                    "RNA",
                    "Research Personnel",
                    "Risk",
                    "Safety",
                    "Signal Transduction",
                    "Surface",
                    "T-Lymphocyte",
                    "Tissue Engineering",
                    "Transcript",
                    "Vaccination",
                    "Vaccines",
                    "cellular engineering",
                    "chimeric antigen receptor",
                    "chimeric antigen receptor T cells",
                    "coronavirus disease",
                    "cost",
                    "cytokine",
                    "delivery vehicle",
                    "design",
                    "empowerment",
                    "extracellular",
                    "immunoengineering",
                    "improved",
                    "in vivo",
                    "mRNA delivery",
                    "manufacture",
                    "notch protein",
                    "novel",
                    "novel therapeutics",
                    "receptor",
                    "response",
                    "senescence",
                    "tool",
                    "vaccine efficacy"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12303",
            "attributes": {
                "award_id": "1K26DK138380-01",
                "title": "Mentoring Emerging Researchers at CHLA (MERCH-LA)",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 28206,
                        "first_name": "LISA M",
                        "last_name": "SPAIN",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-15",
                "end_date": "2028-08-31",
                "award_amount": 98506,
                "principal_investigator": {
                    "id": 25631,
                    "first_name": "Senta K",
                    "last_name": "Georgia",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1555,
                    "ror": "https://ror.org/00412ts95",
                    "name": "Children's Hospital of Los Angeles",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Beta cell dysfunction and death are significant pathologies underlying the development of Type 2 diabetes. There is both clinical and molecular evidence that the pathogenesis of COVID19 may have acute and specific effects on pancreatic beta cell function. One of the barriers to understanding how SARS-CoV2 infection may affect beta cell function and survival in patients is the limited number of physiologically relevant animal models to study. We have capitalized on unique access the pancreas of SCV2-innoculated animals to model and understand how SARS-CoV2 infection affects beta cell survival, metabolism, and function. There is controversy in the literature regarding if SARS-COV2 directly infects beta cells and affects beta cell function and survival or if the disruption of glucose homeostasis in patients is secondary. We hypothesize that SARS-CoV2 infection directly and acutely compromises beta cell function and survival by reprogramming cellular metabolism, thus leaving hosts susceptible to diabetes during or after infection. These highly innovative experiments capitalize on a unique and clinically relevant model system and employs cutting edge techniques to assess how beta cell survival and metabolism are affected by SARS-CoV2 infection. These experiments will provide critical mechanistic insight to the underpinnings of the emerging clinical phenotype of acute hyperglycemia, diabetic ketoacidosis, and potentially lifelong diabetes that may afflict a significant number of patients who have recovered from COVID19. The objective of this proposal is to protect the PI’s time to provide culturally-aware mentoring and intensive training to graduate students from historically underrepresented backgrounds participating in this innovative research program. This objective dovetails with the PI’s immediate and long terms goals, which are to: (1) establish MERCH-LA (Mentoring Emerging Researchers at Children’s Hospital Los Angeles) as a fundamental part of the educational and research infrastructure at CHLA and (2) longitudinally track and quantify outcomes for MERCH-LA graduates into bioscience-related post-graduate careers.",
                "keywords": [
                    "2019-nCoV",
                    "Acute",
                    "Address",
                    "Affect",
                    "African American",
                    "Animal Model",
                    "Animals",
                    "Atrophic",
                    "Autopsy",
                    "Award",
                    "Awareness",
                    "Beta Cell",
                    "Biological Models",
                    "Biological Sciences",
                    "Biomedical Research",
                    "COVID-19",
                    "COVID-19 impact",
                    "COVID-19 pathogenesis",
                    "COVID-19 patient",
                    "COVID-19 survivors",
                    "Cadaver",
                    "Career Mobility",
                    "Cell Respiration",
                    "Cell Survival",
                    "Cell physiology",
                    "Cellular Metabolic Process",
                    "Cessation of life",
                    "Clinical",
                    "Competence",
                    "Data",
                    "Development",
                    "Diabetes Mellitus",
                    "Diabetic Ketoacidosis",
                    "Disease",
                    "Education",
                    "Environment",
                    "Face",
                    "Functional disorder",
                    "Future",
                    "Glucose",
                    "Goals",
                    "Health",
                    "Human",
                    "Hyperglycemia",
                    "In Vitro",
                    "Infection",
                    "Injury",
                    "Insulin",
                    "Islets of Langerhans Transplantation",
                    "Kidney",
                    "Laboratories",
                    "Literature",
                    "Long COVID",
                    "Los Angeles",
                    "Macaca mulatta",
                    "Measures",
                    "Mediating",
                    "Mentors",
                    "Metabolic",
                    "Metabolism",
                    "Mission",
                    "Mitochondria",
                    "Modeling",
                    "Molecular",
                    "Morphology",
                    "Mus",
                    "Non-Insulin-Dependent Diabetes Mellitus",
                    "Odds Ratio",
                    "Outcome",
                    "Pancreas",
                    "Paper",
                    "Pathogenesis",
                    "Pathology",
                    "Patients",
                    "Pediatric Hospitals",
                    "Physiological",
                    "Post-Acute Sequelae of SARS-CoV-2 Infection",
                    "Predisposition",
                    "Prevalence",
                    "Principal Investigator",
                    "Public Health",
                    "Reporting",
                    "Reproducibility",
                    "Research",
                    "Research Infrastructure",
                    "Research Personnel",
                    "Research Project Grants",
                    "Research Training",
                    "Resolution",
                    "Respiratory System",
                    "SARS-CoV-2 infection",
                    "SARS-CoV-2 pathogenesis",
                    "Secondary to",
                    "Stress",
                    "Structure",
                    "Structure of beta Cell of islet",
                    "Study models",
                    "Symptoms",
                    "Techniques",
                    "Testing",
                    "Time",
                    "Training",
                    "Transplantation",
                    "Viral Pathogenesis",
                    "Woman",
                    "blood glucose regulation",
                    "capsule",
                    "career",
                    "career preparation",
                    "clinical phenotype",
                    "clinically relevant",
                    "diabetes pathogenesis",
                    "empowerment",
                    "experience",
                    "experimental study",
                    "graduate student",
                    "improved",
                    "in vivo",
                    "in vivo Model",
                    "innovation",
                    "insight",
                    "insulin secretion",
                    "islet",
                    "long term consequences of COVID-19",
                    "long term recovery",
                    "next generation",
                    "nonhuman primate",
                    "post-transplant",
                    "programs",
                    "severe COVID-19",
                    "skills",
                    "small molecule",
                    "student mentoring",
                    "time use"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "12304",
            "attributes": {
                "award_id": "1R01DA059394-01A1",
                "title": "Wastewater Sampling: A New Tool to Accelerate Ending the HIV Epidemic",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute on Drug Abuse (NIDA)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 21884,
                        "first_name": "PETER",
                        "last_name": "HARTSOCK",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2023-09-15",
                "end_date": "2028-07-31",
                "award_amount": 776846,
                "principal_investigator": {
                    "id": 28207,
                    "first_name": "Thomas P",
                    "last_name": "Giordano",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 566,
                    "ror": "https://ror.org/02pttbw34",
                    "name": "Baylor College of Medicine",
                    "address": "",
                    "city": "",
                    "state": "TX",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Current estimates are that 57% of persons in the U.S. with HIV are suppressed, leaving 43% unsuppressed, including about 13% who are undiagnosed and 30% who have been diagnosed but are not currently suppressed. Identifying persons with unsuppressed HIV to link them to care and antiretroviral treatment (ART) is critical for improving health and reducing new infections. New epidemiologic tools that identify in real time communities with high amounts of circulating HIV may enhance efforts to reduce HIV transmission and substantially contribute to ending the HIV epidemic. During the SARS-CoV-2 (SCV2) pandemic, we and others used “wastewater environmental virology” to monitor and respond to COVID. It uses viral capture and PCR detection of viral nucleic acid from wastewater collection sites to detect, quantify, and predict total SCV2 activity in time. We built a robust and mature wastewater sampling program for the Houston region that includes weekly assessment of 39 wastewater collection sites covering about 4 million residents. Our recent preliminary data demonstrate that HIV is detected in wastewater. Wastewater testing is unbiased, comprehensive, real-time, quantitative, and not influenced by access to health care, stigma or denial. We hypothesize that our pioneering wastewater sampling program can be applied as a powerful new tool to identify geographic areas with a high active burden of HIV, reflecting substantial numbers of people with undiagnosed or untreated HIV infection. Resources can then be mobilized to these communities to enhance HIV outreach, testing, prevention and linkage to care. The specifics aims are: 1) To develop a sensitive, reproducible, and streamlined wastewater HIV detection pipeline; 2) To develop epidemiologic models incorporating data from wastewater sampling as a novel and informative parameter along with routine surveillance data on HIV diagnoses and population data; 3) To characterize and incorporate stakeholder preferences, priorities, and recommendations for engaging key community stakeholders in the HIV wastewater sampling program with consideration to the ethical, legal, social, and cultural contexts of individuals living in target neighborhoods; 4) To determine if delivering proven public health interventions to neighborhoods as directed by wastewater data can reduce the wastewater viral load and increase HIV diagnoses in those neighborhoods. This research will enhance the Respond pillar of the End the HIV Epidemic (EHE) strategy. It will leverage and strengthen partnerships between the researchers and the Houston Health Department, the regional public health authority overseeing many EHE programs in Houston. The work in Houston, a high priority EHE region, will result in: (i) the US’s only HIV wastewater sampling program, (ii) epidemiologic models enhanced with wastewater data that identify unmet testing and treatment needs, (iii) community-informed and ethically appropriate, real-time public health monitoring that reduces the number of people with unsuppressed HIV, and (iv) tools and expertise that can be disseminated to other areas.",
                "keywords": [
                    "2019-nCoV",
                    "Acceleration",
                    "Area",
                    "Authorization documentation",
                    "Bioethics Consultants",
                    "COVID-19",
                    "COVID-19 monitoring",
                    "COVID-19 outbreak",
                    "COVID-19 pandemic",
                    "Caring",
                    "Clinical Data",
                    "Collection",
                    "Communities",
                    "Complex",
                    "Data",
                    "Data Reporting",
                    "Detection",
                    "Diagnosis",
                    "Diagnostic",
                    "Diagnostic tests",
                    "Disease Outbreaks",
                    "Epidemic",
                    "Epidemiologist",
                    "Epidemiology",
                    "Ethics",
                    "Geographic Locations",
                    "Geography",
                    "HIV",
                    "HIV Infections",
                    "HIV diagnosis",
                    "Health",
                    "Human",
                    "Human immunodeficiency virus test",
                    "Individual",
                    "Infection",
                    "Laboratories",
                    "Link",
                    "Methods",
                    "Monitor",
                    "Neighborhoods",
                    "Nose",
                    "Nucleic Acids",
                    "Periodicals",
                    "Persons",
                    "Physicians",
                    "Plants",
                    "Poliomyelitis",
                    "Population",
                    "Prevention",
                    "Public Health",
                    "Recommendation",
                    "Reporting",
                    "Reproducibility",
                    "Research",
                    "Research Personnel",
                    "Resolution",
                    "Resources",
                    "Sewage",
                    "Sexual Partners",
                    "Signal Transduction",
                    "Site",
                    "Testing",
                    "Time",
                    "Viral",
                    "Viral Load result",
                    "Work",
                    "antiretroviral therapy",
                    "authority",
                    "coronavirus disease",
                    "epidemiological model",
                    "ethical  legal  and social implication",
                    "experience",
                    "health care availability",
                    "improved",
                    "novel",
                    "novel strategies",
                    "outreach",
                    "predictive modeling",
                    "preference",
                    "programs",
                    "public health intervention",
                    "routine care",
                    "sewage treatment",
                    "social stigma",
                    "success",
                    "surveillance data",
                    "tool",
                    "transmission process",
                    "viral detection",
                    "virology",
                    "wastewater sampling",
                    "wastewater testing"
                ],
                "approved": true
            }
        }
    ],
    "meta": {
        "pagination": {
            "page": 1405,
            "pages": 1442,
            "count": 14420
        }
    }
}